The future of the global hemophilia treatment market looks promising with opportunities in the hemophilia A and hemophilia B markets. The global hemophilia treatment market is expected to reach an estimated $18.4 billion by 2030 with a CAGR of 5.2% from 2024 to 2030. The major drivers for this market are large numbers of hemophilia patients, usage of prophylactic treatment for hemophilia, and favorable government initiatives.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the hemophilia treatment
market by type (hemophilia A and hemophilia B), drug therapy (recombinant
coagulation factor concentrates therapy, plasma derived coagulation factor
concentrates therapy, and non-factor replacement therapy), end use (hospitals, clinics,
and others), and region (North America, Europe, Asia Pacific, and the Rest of
the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the industry?
Market Segmentation:
In this market,
recombinant coagulation factor concentrates therapy, plasma derived coagulation
factor concentrates therapy, non-factor replacement therapy are the major
segments of hemophilia treatment market by drug therapy. Lucintel forecasts
that recombinant coagulation factor concentrates therapy will remain the
largest segment over the forecast period because of the large number of
recombinant technology products available for the treatment.Within this market,
hemophilia A will remain the largest segment due to growing incidence of
hemophilia A, increased use of factor VIII, along with improvements in
technology for treating hemophilia and regulatory bodies' approval of products.
Europe will remain the
largest region over the forecast period due to increasing number of hemophilic
patients and rising awareness about technologically advanced products in the
region.
Baxter, Octapharma, CSL
Limited, Grifols, Bayer, Pfizer, Sanofi, Ferring, Biomarin, and Sangamo
Therapeutics are the major suppliers in the hemophilia treatment market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Explore Our Latest Publications
Cancer Monoclonal Antibodies
Market
Enzyme-Linked Immunosorbent
Assay (ELISA) Tests Market
Fluorescent in Situ Hybridization
(FISH) Market
Microbial Identification Market
Transfection Reagent and Equipment
Market
No comments:
Post a Comment